

# Research Journal of Pharmaceutical, Biological and Chemical Sciences

## Evaluating the Efficacy of Multimodal Analgesia in Orthopedic Surgeries: A Randomized Controlled Trial.

Priya Paralikar<sup>1\*</sup>, Kiran Dhonnar<sup>2</sup>, Archana Ghotale<sup>3</sup>, and Sneha Nannaware<sup>4</sup>.

<sup>1</sup>Assistant Professor, Department of Anesthesiology, GMC and MPGIMER MUHS Nashik, Maharashtra, India.

<sup>2</sup>Consultant Anesthetist (Specialist), Civil Hospital, Nashik, Maharashtra, India.

<sup>3</sup>Assistant Professor, Department of Anesthesiology, GMC and MPGIMER MUHS Nashik, Maharashtra, India.

<sup>4</sup>Assistant Professor, Department of Anesthesiology, GMC and MPGIMER MUHS Nashik, Maharashtra, India.

### ABSTRACT

Effective pain management in orthopedic surgeries is essential for improved recovery and patient outcomes. Multimodal analgesia, combining different analgesic agents and techniques, offers a promising alternative to opioid-based regimens, reducing pain and opioid-related side effects. To evaluate the efficacy and safety of multimodal analgesia compared to conventional opioid-based regimens in patients undergoing orthopedic surgeries. A randomized controlled trial was conducted with 40 patients aged 18–65 years undergoing elective orthopedic surgeries. Patients were randomized into two groups: multimodal analgesia (n=20) and conventional opioid-based analgesia (n=20). Pain scores (VAS), opioid consumption, time to mobilization, and adverse effects were assessed over 48 hours postoperatively. Data were analyzed using SPSS 23, with  $p < 0.05$  considered significant. Multimodal analgesia demonstrated significantly lower VAS pain scores ( $p < 0.01$ ), reduced opioid consumption ( $14.5 \pm 3.6$  mg vs.  $28.2 \pm 4.5$  mg,  $p < 0.01$ ), and faster mobilization ( $16.8 \pm 3.5$  hours vs.  $22.6 \pm 4.2$  hours,  $p < 0.01$ ). Adverse effects such as nausea, constipation, and dizziness were also significantly lower in the multimodal group. Multimodal analgesia is a superior approach for postoperative pain management in orthopedic surgeries, offering better pain control, reduced opioid use, and improved recovery outcomes.

**Keywords:** Multimodal analgesia, orthopedic surgery, postoperative pain management

<https://doi.org/10.33887/rjpbc/2024.15.6.96>

*\*Corresponding author*

## INTRODUCTION

Effective postoperative pain management is a cornerstone of successful surgical outcomes, particularly in orthopedic surgeries, which are often associated with significant pain due to extensive tissue manipulation [1]. Poorly managed pain can lead to delayed recovery, decreased patient satisfaction, and increased risk of complications such as chronic pain syndromes and impaired mobility. Traditional approaches to pain management in orthopedic patients have primarily relied on opioid-based regimens. However, the widespread use of opioids is accompanied by well-documented adverse effects, including nausea, constipation, respiratory depression, and the potential for addiction [2, 3].

In response to these limitations, multimodal analgesia has emerged as a promising strategy for postoperative pain control. This approach integrates two or more analgesic agents or techniques that target different pain pathways, thereby enhancing pain relief while minimizing reliance on opioids. Common modalities include the use of nonsteroidal anti-inflammatory drugs (NSAIDs), regional nerve blocks, acetaminophen, gabapentinoids, and local anesthetics [4].

This randomized controlled trial aims to evaluate the efficacy and safety of multimodal analgesia compared to conventional opioid-based regimens in patients undergoing orthopedic surgeries. The study seeks to determine whether multimodal analgesia provides superior pain control, enhances functional recovery, and reduces opioid-related adverse effects, thereby improving overall patient outcomes.

## STUDY METHODOLOGY

This randomized controlled trial was conducted to evaluate the efficacy of multimodal analgesia in patients undergoing orthopedic surgeries. Ethical clearance was obtained from the institutional ethics committee prior to study initiation. Informed consent was secured from all participants after explaining the purpose, methodology, and potential risks and benefits of the study. A total of 40 patients, aged 18-65 years, scheduled for elective orthopedic surgeries, were included. Patients with known allergies to study medications, chronic pain conditions, or significant comorbidities were excluded.

Participants were randomized into two groups of 20 each using a computer-generated randomization sequence. The intervention group received multimodal analgesia, consisting of preoperative oral acetaminophen, gabapentin, and regional nerve blocks with local anesthetics. Postoperative pain management included scheduled NSAIDs and rescue opioids as needed. The control group received conventional opioid-based analgesia, with opioids administered as per routine hospital protocol. Both groups were managed by the same surgical and anesthetic teams to ensure consistency.

Pain assessment was carried out using the Visual Analog Scale (VAS) at regular intervals: immediately postoperatively, at 6, 12, 24, and 48 hours. Secondary outcomes included opioid consumption, time to mobilization, incidence of adverse effects, and patient satisfaction, which were recorded by blinded assessors. Data on postoperative complications, if any, were also documented.

Statistical analysis was performed using SPSS version 23. Continuous variables were expressed as mean  $\pm$  standard deviation and compared using the independent t-test, while categorical variables were expressed as frequencies and percentages, analyzed using the chi-square test. A p-value of  $<0.05$  was considered statistically significant. The results were presented in tabular and graphical formats for clarity.

## RESULTS

**Table 1: Demographic Characteristics of the Study Population (n=40)**

| Variable                   | Multimodal Group (n=20) | Conventional Group (n=20) | p-value |
|----------------------------|-------------------------|---------------------------|---------|
| Age (mean $\pm$ SD)        | 45.6 $\pm$ 10.3         | 47.2 $\pm$ 11.1           | 0.62    |
| Gender (Male/Female)       | 12/8                    | 10/10                     | 0.55    |
| BMI (mean $\pm$ SD)        | 25.4 $\pm$ 2.3          | 25.1 $\pm$ 2.7            | 0.78    |
| Surgery Type (Major/Minor) | 15/5                    | 14/6                      | 0.72    |

**Table 2: Pain Scores (VAS) Over Time**

| Timepoint         | Multimodal Group (mean $\pm$ SD) | Conventional Group (mean $\pm$ SD) | p-value |
|-------------------|----------------------------------|------------------------------------|---------|
| Immediate Post-op | 4.5 $\pm$ 1.2                    | 6.3 $\pm$ 1.4                      | <0.01   |
| 6 hours           | 3.8 $\pm$ 1.0                    | 5.7 $\pm$ 1.3                      | <0.01   |
| 12 hours          | 3.0 $\pm$ 1.1                    | 4.8 $\pm$ 1.2                      | <0.01   |
| 24 hours          | 2.5 $\pm$ 0.9                    | 4.0 $\pm$ 1.0                      | <0.01   |
| 48 hours          | 2.0 $\pm$ 0.8                    | 3.5 $\pm$ 1.1                      | <0.01   |

**Table 3: Opioid Consumption (mg Morphine Equivalent)**

| Time Period      | Multimodal Group (mean $\pm$ SD) | Conventional Group (mean $\pm$ SD) | p-value |
|------------------|----------------------------------|------------------------------------|---------|
| 0-24 hours       | 8.5 $\pm$ 2.1                    | 15.4 $\pm$ 3.2                     | <0.01   |
| 24-48 hours      | 6.0 $\pm$ 1.8                    | 12.8 $\pm$ 2.7                     | <0.01   |
| Total (48 hours) | 14.5 $\pm$ 3.6                   | 28.2 $\pm$ 4.5                     | <0.01   |

**Table 4: Time to Mobilization (Hours)**

| Group              | Time to Mobilization (mean $\pm$ SD) | p-value |
|--------------------|--------------------------------------|---------|
| Multimodal Group   | 16.8 $\pm$ 3.5                       | <0.01   |
| Conventional Group | 22.6 $\pm$ 4.2                       |         |

**Table 5: Incidence of Adverse Effects**

| Adverse Effect             | Multimodal Group (n=20) | Conventional Group (n=20) | p-value |
|----------------------------|-------------------------|---------------------------|---------|
| Nausea/Vomiting (%)        | 3 (15%)                 | 8 (40%)                   | 0.04    |
| Constipation (%)           | 2 (10%)                 | 7 (35%)                   | 0.03    |
| Respiratory Depression (%) | 0 (0%)                  | 2 (10%)                   | 0.15    |
| Dizziness (%)              | 1 (5%)                  | 6 (30%)                   | 0.02    |

## DISCUSSION

This randomized controlled trial evaluated the efficacy of multimodal analgesia compared to conventional opioid-based regimens in patients undergoing orthopedic surgeries. The findings demonstrate the superiority of multimodal analgesia in pain control, reduced opioid consumption, faster mobilization, and a lower incidence of adverse effects, thus highlighting its potential as a safer and more effective postoperative pain management strategy [6-8].

### Pain Control

The study results reveal significantly lower pain scores in the multimodal analgesia group compared to the conventional group across all postoperative time points. The Visual Analog Scale (VAS) scores at immediate postoperative, 6-hour, 12-hour, 24-hour, and 48-hour intervals consistently showed statistically significant differences ( $p < 0.01$ ). These findings corroborate previous studies suggesting that multimodal analgesia, by targeting multiple pain pathways, provides superior analgesia compared to opioid-only regimens. For example, the addition of regional nerve blocks and preemptive use of acetaminophen and gabapentin likely contributed to these enhanced pain relief outcomes. Effective pain management is crucial for improving patient satisfaction, reducing stress responses, and facilitating recovery, underscoring the clinical value of multimodal approaches.

### Opioid Consumption

Opioid consumption, measured in morphine equivalents, was significantly lower in the multimodal group at both the 0-24 hour and 24-48 hour intervals. The total opioid consumption over 48 hours was reduced by nearly 50% in the multimodal group (14.5  $\pm$  3.6 mg vs. 28.2  $\pm$  4.5 mg,  $p < 0.01$ ). This reduction aligns with the core objective of multimodal analgesia: minimizing opioid use to mitigate associated adverse effects. Lower opioid requirements not only reduce the risk of dependence but also decrease the likelihood of opioid-related complications, such as respiratory depression, nausea, and

constipation. These findings are consistent with previous research highlighting multimodal analgesia as an effective opioid-sparing strategy, making it a critical component of enhanced recovery protocols in orthopedic surgery.

### **Faster Mobilization**

The time to mobilization was significantly shorter in the multimodal group ( $16.8 \pm 3.5$  hours) compared to the conventional group ( $22.6 \pm 4.2$  hours,  $p < 0.01$ ). Early mobilization is a vital factor in postoperative recovery, particularly in orthopedic patients, as it reduces the risk of complications such as deep vein thrombosis, improves functional outcomes, and shortens hospital stays. The reduced pain and lower sedation levels in the multimodal group likely contributed to this outcome, highlighting the broader benefits of effective pain management beyond mere analgesia. These results reinforce the growing body of evidence supporting multimodal analgesia as an essential component of enhanced recovery after surgery (ERAS) pathways [9].

### **Adverse Effects**

The incidence of adverse effects was significantly lower in the multimodal group. Nausea and vomiting, experienced by 40% of patients in the conventional group, occurred in only 15% of the multimodal group ( $p = 0.04$ ). Similarly, the incidence of constipation was reduced from 35% to 10% ( $p = 0.03$ ), and dizziness decreased from 30% to 5% ( $p = 0.02$ ). Respiratory depression was reported in 10% of the conventional group, whereas no cases were observed in the multimodal group, though this difference did not reach statistical significance ( $p = 0.15$ ). These results are clinically significant, as opioid-related side effects are a common barrier to effective recovery. By reducing these adverse effects, multimodal analgesia not only enhances patient comfort but also improves overall safety and satisfaction [10].

### **Implications for Clinical Practice**

The findings of this study have significant implications for clinical practice. Multimodal analgesia provides a comprehensive approach to pain management that aligns with the principles of ERAS protocols. The reduced pain scores, lower opioid consumption, faster mobilization, and decreased adverse effects observed in this study suggest that multimodal analgesia should be considered a standard of care for postoperative pain management in orthopedic surgeries. Furthermore, the opioid-sparing benefits of multimodal analgesia are particularly relevant in the context of the ongoing opioid crisis, offering a practical solution to mitigate the risks of opioid dependence and misuse.

While the study provides valuable insights, it is not without limitations. The sample size of 40 patients, though adequate for preliminary analysis, limits the generalizability of the findings. A larger, multicenter trial would provide more robust evidence. Additionally, the study was conducted in a single institution, and the results may not be universally applicable across different healthcare settings with varying resources and practices. Finally, the study focused on short-term outcomes, and further research is needed to assess the long-term benefits and potential risks of multimodal analgesia.

## **CONCLUSION**

This study demonstrates that multimodal analgesia is a safe and effective strategy for managing postoperative pain in orthopedic surgeries. By providing superior pain control, reducing opioid consumption, facilitating early mobilization, and minimizing adverse effects, multimodal analgesia offers significant advantages over conventional opioid-based regimens. These findings highlight the need for broader implementation of multimodal analgesia protocols in clinical practice to enhance recovery and improve patient outcomes. Future research should continue to explore its long-term benefits and adaptability to various clinical settings to ensure its optimal utilization in perioperative care.

## **REFERENCES**

- [1] Hinthner A, Nakoneshny SC, Chandarana SP, Matthews TW, Hart R, Schrag C, Matthews J, McKenzie CD, Fick GH, Dort JC. Efficacy of Multimodal Analgesia for Postoperative Pain Management in Head and Neck Cancer Patients. *Cancers (Basel)*. 2021 Mar 12;13(6):1266.

- [2] van den Beuken-van Everdingen M.H.J., de Rijke J.M., Kessels A.G., Schouten H.C., van Kleef M., Patijn J. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. *Ann. Oncol.* 2007;18:1437–1449.
- [3] Orgill R., Krempf G.A., Medina J.E. Acute pain management following laryngectomy. *Arch. Otolaryngol. Head Neck Surg.* 2002;128:829–832.
- [4] Hinthar A., Nakoneshny S.C., Chandarana S.P., Wayne Matthews T., Dort J.C. Efficacy of postoperative pain management in head and neck cancer patients. *Otolaryngol. Head Neck Surg.* 2018;47:29.
- [5] Hinthar A., Abdel-Rahman O., Cheung W.Y., Quan M.L., Dort J.C. Chronic Postoperative Opioid Use: A Systematic Review. *World J. Surg.* 2019;43:2164–2174.
- [6] Inacio M.C., Hansen C., Pratt N.L., Graves S.E., Roughead E.E. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: A retrospective cohort study. *BMJ Open.* 2016;6:e010664.
- [7] Clarke H., Soneji N., Ko D.T., Yun L., Wijesundera D.N. Rates and risk factors for prolonged opioid use after major surgery: Population-based cohort study. *BMJ.* 2014;348:g1251
- [8] Alam A., Gomes T., Zheng H., Mamdani M.M., Juurlink D.N., Bell C.M. Long-term analgesic use after low-risk surgery: A retrospective cohort study. *Arch. Intern. Med.* 2012;172:425–430.
- [9] Pang J., Tringale K.R., Tapia V.J., Moss W.J., May M.E., Furnish T., Barnachea L., Brumund K.T., Sacco A.G., Weisman R.A., et al. Chronic Opioid Use Following Surgery for Oral Cavity Cancer. *JAMA Otolaryngol. Head Neck Surg.* 2017;143:1187–1194.
- [10] Manchikanti L., Helm S., Fellows B., Janata J.W., Pampati V., Grider J.S., Boswell M.V. Opioid epidemic in the United States. *Pain Physician.* 2012;15:ES9–ES38